Literature DB >> 35924979

The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation.

Anna Yeaton1,2, Geraldine Cayanan1,2, Iannis Aifantis1,2, Maria Guillamot1,2, Sanam Loghavi3, Igor Dolgalev4, Emmett M Leddin5,6, Christian E Loo7, Hedieh Torabifard5,6, Deedra Nicolet8,9, Jingjing Wang1,2, Kate Corrigan1,2, Varvara Paraskevopoulou1,2, Daniel T Starczynowski10,11,12, Eric Wang13, Omar Abdel-Wahab13, Aaron D Viny14,15,16, Richard M Stone17, John C Byrd18, Olga A Guryanova19, Rahul M Kohli7, G Andrés Cisneros5,6, Aristotelis Tsirigos4, Ann-Kathrin Eisfeld8,20.   

Abstract

Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated preleukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation frequently found in patients with CH and leukemia. In a fashion similar to CH, animals show signs of disease late in life when they develop a wide range of myeloid neoplasms, including acute myeloid leukemia (AML). Using single-cell transcriptomic profiling of the bone marrow, we show that disease progression in aged animals correlates with an enhanced inflammatory response and the emergence of an aberrant inflammatory monocytic cell population. The gene signature characteristic of this inflammatory population is associated with poor prognosis in patients with AML. Our study illustrates an example of collaboration between a genetic lesion found in CH and inflammation, leading to transformation and the establishment of blood neoplasms. SIGNIFICANCE: Progression from a preleukemic state to transformation, in the presence of TET2 mutations, is coupled with the emergence of inflammation and a novel population of inflammatory monocytes. Genes characteristic of this inflammatory population are associated with the worst prognosis in patients with AML. These studies connect inflammation to progression to leukemia. See related commentary by Pietras and DeGregori, p. 2234 . This article is highlighted in the In This Issue feature, p. 2221. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 35924979      PMCID: PMC9547930          DOI: 10.1158/2159-8290.CD-21-1146

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  78 in total

Review 1.  Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:  David P Steensma
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.

Authors:  Zhigang Cai; Jonathan J Kotzin; Baskar Ramdas; Sisi Chen; Sai Nelanuthala; Lakshmi Reddy Palam; Ruchi Pandey; Raghuveer Singh Mali; Yan Liu; Mark R Kelley; George Sandusky; Morvarid Mohseni; Adam Williams; Jorge Henao-Mejia; Reuben Kapur
Journal:  Cell Stem Cell       Date:  2018-12-06       Impact factor: 24.633

3.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

Authors:  Kelly Moran-Crusio; Linsey Reavie; Alan Shih; Omar Abdel-Wahab; Delphine Ndiaye-Lobry; Camille Lobry; Maria E Figueroa; Aparna Vasanthakumar; Jay Patel; Xinyang Zhao; Fabiana Perna; Suveg Pandey; Jozef Madzo; Chunxiao Song; Qing Dai; Chuan He; Sherif Ibrahim; Miloslav Beran; Jiri Zavadil; Stephen D Nimer; Ari Melnick; Lucy A Godley; Iannis Aifantis; Ross L Levine
Journal:  Cancer Cell       Date:  2011-06-30       Impact factor: 31.743

4.  BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis.

Authors:  Eva Kaufmann; Joaquin Sanz; Jonathan L Dunn; Nargis Khan; Laura E Mendonça; Alain Pacis; Fanny Tzelepis; Erwan Pernet; Anne Dumaine; Jean-Christophe Grenier; Florence Mailhot-Léonard; Eisha Ahmed; Jad Belle; Rickvinder Besla; Bruce Mazer; Irah L King; Anastasia Nijnik; Clinton S Robbins; Luis B Barreiro; Maziar Divangahi
Journal:  Cell       Date:  2018-01-11       Impact factor: 41.582

5.  Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.

Authors:  J O Moore; R K Dodge; P C Amrein; J Kolitz; E J Lee; B Powell; S Godfrey; F Robert; C A Schiffer
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

6.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

7.  Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Authors:  Eyal C Attar; Jeffrey L Johnson; Philip C Amrein; Gerard Lozanski; Martha Wadleigh; Daniel J DeAngelo; Jonathan E Kolitz; Bayard L Powell; Peter Voorhees; Eunice S Wang; William Blum; Richard M Stone; Guido Marcucci; Clara D Bloomfield; Barry Moser; Richard A Larson
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

8.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.

Authors:  Siddhartha Jaiswal; Pradeep Natarajan; Alexander J Silver; Christopher J Gibson; Alexander G Bick; Eugenia Shvartz; Marie McConkey; Namrata Gupta; Stacey Gabriel; Diego Ardissino; Usman Baber; Roxana Mehran; Valentin Fuster; John Danesh; Philippe Frossard; Danish Saleheen; Olle Melander; Galina K Sukhova; Donna Neuberg; Peter Libby; Sekar Kathiresan; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2017-06-21       Impact factor: 91.245

Review 9.  Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection.

Authors:  Eric M Pietras; Markus G Manz; Francisco Caiado
Journal:  J Exp Med       Date:  2021-06-15       Impact factor: 14.307

Review 10.  Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia.

Authors:  M Ryan Corces; Howard Y Chang; Ravindra Majeti
Journal:  Front Oncol       Date:  2017-11-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.